Published in final edited form as:

Bioorg Med Chem Lett. 2008 May 1; 18(9): 2840–2844. doi:10.1016/j.bmcl.2008.03.079.

Discovery of a novel submicromolar inhibitor of the lymphoid specific tyrosine phosphatase

Yuli Xie^a, Yidong Liu^a, Gangli Gong^a, Alison Rinderspacher^a, Shi-Xian Deng^a, Deborah H. Smith^b, Udo Toeppen^b, Effie Tzilianos^b, Lars Branden^b, Dušica Vidović^c, Caty Chung^c, Stephan Schürer^c, Lutz Tautz^d, and Donald W. Landry^{a,*}

^aDepartment of Medicine, Columbia University, 650 W 168th St, BB 1029, New York, NY 10032

^bDepartment of Physiology and Cellular Biophysics, Columbia University, New York, NY 10032

^cScientific Computing, The Scripps Research Institute, Jupiter, FL 33458

^dInfectious and Inflammatory Disease Center, Burnham Institute for Medical Research, La Jolla, CA 92037

Abstract

We report here a class of thiazolidine-2,4-diones and 2-thioxothiazolidin-4-ones as potent inhibitors of the lymphoid specific tyrosine phosphatase (Lyp) identified from high throughput screens. Chemical modification by incorporating known phosphotyrosine (pTyr) mimics led to discovery of a salicylate-based inhibitor with submicromolar potency.

Keywords

Thiazolidine; Lyp; pTyr mimics; salicylate

The lymphoid specific phosphatase (Lyp), encoded by the PTPN22 gene, plays an important role in T cell signaling. A single-nucleotide polymorphism in PTPN22 is associated with autoimmune disorders such as type 1 diabetes, rheumatoid arthritis, systemic lupus erythematosus and Grave's disease. The autoimmunity-predisposing allele corresponds to a gain-of-function mutation, producing a variant phosphatase that is more active than the wild type enzyme in inhibiting T cell signaling.^{1,2} Inhibition of Lyp therefore provides a novel approach to the treatment of a broad spectrum of autoimmune diseases.

To identify small molecule inhibitors of Lyp, high-throughput screens were performed at Columbia University as part of the Molecular Library Screening Center Network (MLSCN) of the NIH Roadmap for Medical Research. The Lyp assay³ was established using a bacterially expressed fully active 62 KDa N-terminal catalytic domain of Lyp. Compounds were assayed for their capacity to inhibit Lyp-catalyzed conversion of DiFMUP(6,8-difluoro-4-methylumbelliferyl phosphate) to a fluorescent product. Fluorescence with excitation at 360nm and emission at 465 nm was recorded at the endpoint of the reaction. From the compound libraries provided by NIH, a variety of active hits were identified through the high throughput screens and confirmed manually by the dose-response assays. Intriguingly, a number of these

* Corresponding author. Tel: +1 212 3055839; Fax: +1 212 3053475; Email: E-mail: dwl1@columbia.edu.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

compounds share a thiazolidine core structure and thus form an active cluster, providing a starting point for the assessment of structure-activity relationships and medicinal chemistry efforts (Figure 1).

Protein tyrosine phosphatases (PTPases) share a highly conserved active site, the phosphotyrosine (pTyr) binding pocket that is the main target for PTPase inhibitor design. Thus, most inhibitors share a pharmacophore structurally similar to the pTyr substrate. Effective pTyr mimics are often charged bidentate anions that competitively bind to the highly polarized pTyr pocket. Several classes of mimics have been reported,⁴ including the difluoromethylenephosphonates (DFMP) and benzoic acids such as 2-(oxalylamino)-benzoic acids (OBA), salicylic acids (SA) and its derivatives (Figure 2).

We noticed that several of the thiazolidine hits contained benzoic acid moiety, and thus could be replaced with a pTyr-mimicking fragment. Fragment-based drug design is a new approach that has been successfully applied to challenging targets.⁵ This strategy allows hits to be optimized by combining and linking different fragments. We reasoned that combining a known pTyr surrogate with the thiazolidine core structure we identified from high throughput screens might result in synergistically improved potency. Salicylic acid and its derivatives, which are potent pTyr surrogates, were chosen as our initial building blocks for novel Lyp inhibitors.

As shown in Scheme 1, a series of thiazolidine-dione and 2-thioxothiazolidin-4-one compounds with an appended salicylic moiety were designed and synthesized.⁶ Dioxothiazolidinyl esters **3a-3d** were synthesized from thiazolidine-2, 4-dione **1** which was first converted to potassium salt **2** by potassium hydroxide and subsequently alkylated with methyl (tert-butyl) bromoacetate in acetone at 50°C, or methyl (tert-butyl) bromopropionate in dimethylformamide at 90°C in the presence of potassium iodide. The acids **4a-4b** were obtained by the treatment of the tert-butyl esters **3c-3d** with trifluoroacetic acid. Suzuki coupling of boronic acid **5a-5b** with 5-iodo-2-hydroxybenzoate **6a-6b** conveniently yielded salicylic acid derived aldehydes **7a-7d**, which were condensed with thiazolidine-diones **3a,3c, 4a, 4b** and commercially available 2-thioxothiazolidin-4-ones **4c-4d** in toluene to afford the final product **8a-8s** in yields of 72-85%.

A triacid analog **11** was synthesized according to Scheme 2.⁶ Alkylation of compound **7a** with 2-bromoacetate gave aldehyde **9**, followed by deprotection of methyl ester with lithium hydroxide to yield aldehyde **10**. Similar condensation of aldehyde **10** and **4d** readily afforded the desired product **11** in a total yield of 62% over three steps.

To further modify the salicylic compounds, Schiff base analogs with the thiazolidinedione head group replaced with the hydantoin ring were synthesized.⁶ As outlined in Scheme 3, simply mixing aldehydes with the hydrochloride salt of 1-aminohydantoin in ethanol readily gave the corresponding Schiff bases **12a-12d** in quantitative yields. The synthesis of **17a** and **17b** started from protection of 1-aminohydantoin with benzaldehyde by forming the imine **13**. Deprotonation of **13** followed by alkylation with bromoacetate provided the imidyl esters **15a** and **15b**. Simultaneous deprotection of ester and imine by refluxing in hydrochloric acid afforded the corresponding amino acid **16**. Condensation between the hydantoin-derived amino acid and aldehydes **7c** and **7d** furnished the Schiff base analogs **17a** and **17b** in good yields.

A total of 25 salicylic compounds were synthesized, and their ability to inhibit Lyp was tested in vitro with IC₅₀s determined from the dose response assays. Results for thiazolidine compounds are summarized in Table 1, while the results for Schiff base analogs are shown in Table 2. 17 compounds showed reasonable activities against Lyp. Among them, compound **8p** was shown to be a submicromolar inhibitor with an impressive IC₅₀ of 0.39 μM. Several structure-activity relationships could be observed from these data. The presence of a free carboxyl group in the molecule is essential for the activity. For example, diester compounds

8b, **8c**, **8d** and **8k** are basically inactive, consistent with the expectation that negative charge is important for the activity of phosphatase inhibitors. As demonstrated by compounds **8j**, **8r**, **8m** and **8q**, the thiophene ring is generally more potent than the furan ring. Interestingly, 2-thione also seems preferable to 2-one in the thiozolidine ring that is best illustrated by increased potency of compound **8a** and **8j**. The length of the side chain ($n=0, 1$ and 2), depending on the overall structure of the compound, has a varying impact on the activities. 2-(carboxymethoxy) benzoic acid (CMBA), a derivative of salicylic acid, is also a potent pTyr mimic. However, our attempt to replace salicylic acid with CMBA resulted in a great loss of activity of compound **11** compared with **8e**, indicating that the free hydroxyl group is necessary for retaining the activity.

Coincidentally, when this manuscript was being prepared, the crystal structure of Lyp in complex with a salicylic acid-based inhibitor was published.⁷ It was shown that the hydroxyl group of salicylic acid makes critical polar interactions in the active site of Lyp.

As can be seen from Table 2, the Schiff base analogs are poor inhibitors in general. Only compound **12d** and **17a** showed moderate activities with the IC_{50} s of $34.0 \mu M$ and $36.0 \mu M$, respectively.

In summary, we have successfully identified a cluster of thiozolidine compounds with good Lyp inhibitory activities via high throughput screening. Improved potency ($<1 \mu M$) was achieved by rational design and chemical synthesis. PTPase selectivity and cell studies of the promising compounds are currently being pursued.

References and notes

1. Bottini N, Musumeci L, Alonso A, Rahmouni S, Nika K, Rostamkhani M, MacMurray J, Meloni GF, Lucarelli P, Pellecchia M, et al. *Nat Genet* 2004;36:337. [PubMed: 15004560]
2. Vang T, Congia M, Macis MD, Musumeci L, Orru V, Zavattari P, Nika K, Tautz L, Tasken K, Cucca F, et al. *Nat Genet* 2005;37:1317. [PubMed: 16273109]
3. See the assay protocol published in PubChem (AID: 606).
4. Burke TR, Lee K. *Acc Chem Res* 2003;36:426. [PubMed: 12809529]
5. Hajduk PJ, Greer J. *Nat Rev Drug Discov* 2007;6(3):211. [PubMed: 17290284]
6. Analytical data for representative compounds: **8p**, 1H NMR (300 MHz, CD_3OD) δ 10.65 (br, 1H), 8.12 (s, 1H), 7.99 (s, 1H), 7.91(d, 1H), 7.68(d, 1H), 7.62 (d, 1H), 7.06(d, 1H), 3.90 (s, 3H), 3.83-3.80 (m, 2H), 2.60-2.55 (m, 2H); ^{13}C NMR (75 MHz, CD_3OD) δ 172.5, 168.8, 166.9, 165.7, 160.6, 149.8, 137.5, 136.2, 133.2, 127.7, 126.8, 125.5, 124.8, 119.3, 118.6, 115.1, 53.4, 38.4, 32.4; ESI-MS($M^+ + H$): 434.3. **11**, 1H NMR (300 MHz, CD_3OD) 8.11 (s, 1H), 7.93 (d, 1H), 7.73(s, 1H), 7.39(d, 1H), 7.31 (d, 1H), 7.22(d, 1H), 4.86 (s, 2H), 4.72 (s, 2H); ^{13}C NMR (75 MHz, CD_3OD) δ 194.2, 170.3, 167.9, 167.3, 166.6, 158.2, 157.7, 149.5, 129.4, 127.6, 124.7, 123.3, 122.0, 120.0, 118.0, 115.2, 110.4, 66.0, 45.8; ESI-MS($M^+ + H$): 464.0. **12d**, 1H NMR (300 MHz, CD_3OD) δ 11.2 (s, 1H), 8.01 (s, 1H), 7.98 (s, 1H), 7.85(d, 1H), 7.43 (d, 1H), 7.35 (d, 1H), 7.01 (d, 1H), 4.32 (s, 2H); ^{13}C NMR (75 MHz, CD_3OD) δ 171.9, 169.5, 161.5, 153.8, 144.6, 138.8, 138.2, 133.4, 132.4, 127.5, 125.3, 124.2, 118.9, 114.3, 49.9; ESI-MS($M^+ + H$): 346.3.
7. Yu, Xiao; Sun, JP.; He, Y.; Guo, X.; Liu, S.; Zhou, B.; Hudmon, A.; Zhang, ZY. *Proc Natl Acad Sci U S A* 2007;104(50):19767. [PubMed: 18056643]

Figure 1.
An active cluster of Lyp inhibitors

Figure 2.
The phosphotyrosine(pTyr) mimic

Scheme 1. The synthesis of Lyp inhibitors **8a-8s**

Scheme 2.
The synthesis of the triacid analog **11**

Scheme 3.
The synthesis of Schiff base analogs

Table 1

The Lyp inhibitory activities of compound **8a-8s** and **11**

Comp	R	R'	n	X	Y	IC ₅₀ (μM) ^a
8a	H	CH ₃	1	O	S	21.0
8b	CH ₃	CH ₃	2	O	O	44.0
8c	CH ₃	CH ₃	2	S	O	>44
8d	CH ₃	CH ₃	1	S	O	>44
8e	H	H	1	O	S	8.7
8f	H	H	2	O	O	5.1
8g	H	H	2	S	O	5.9
8h	H	H	1	S	O	2.8
8i	H	H	1	S	S	5.4
8j	H	H	1	S	S	4.3
8k	CH ₃	CH ₃	1	O	O	>44
8l	H	CH ₃	1	S	O	18
8m	H	CH ₃	1	O	O	>44
8n	H	H	1	O	O	5.6
8o	H	CH ₃	2	O	O	4.3
8p	H	CH ₃	2	S	O	0.39
8q	CH ₃	H	1	O	O	4.8
8r	CH ₃	H	1	S	O	1.8
8s		H	0	O	S	1.4
11						>44

IC_{50} values are determined from a single experiment performed in triplicate

Table 2

The inhibitory activities of the Schiff base analogs

Comp	R	R'	X	IC ₅₀ (μM) ^a
12a	H	CH ₃	O	>44
12b	H	H	O	>44
12c	H	CH ₃	S	>44
12d	H	H	S	34.0
17a	CH ₂ CO ₂ H	H	O	36.0
17b	CH ₂ CO ₂ H	H	S	>44

^aIC₅₀ values are determined from a single experiment performed in triplicate